Protein Kinase Inhibitors: all 15,278 studies that test it

Page 111 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Study of Apatinib and MASCT in Patients With Advanced Solid TumorsStatus unknownNCT02844881Phase 1/2
• Ursodeoxycholic Acid for Rhegmatogenous Retinal DetachmentCompletedNCT02841306Phase 1
• Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA CapsulesCompletedNCT02841150Phase 1
• A Study To Evaluate The Effect Of Itraconazole On Pharmacokinetics Of PF-06463922 In Healthy VolunteersCompletedNCT02838264Phase 1
• Effect of Rifampicin on the Pharmacokinetics of ApatinibCompletedNCT02836821Phase 1
• Effect of Itraconazole on the Pharmacokinetics of ApatinibCompletedNCT02836171Phase 1
• Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRCCompletedNCT02835924Phase 2
• Study of Nintedanib Plus Bevacizumab in Advanced Solid TumorsCompletedNCT02835833Phase 1
• A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 MutationCompletedNCT02834936Phase 2
• BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)CompletedNCT02834364Phase 2
• Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate CancerCompletedNCT02833883Phase 1
• Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerWithdrawnNCT02833506Phase 1
• Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer PatientsCompletedNCT02831530Phase 2
• Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)WithdrawnNCT02829840Phase 1/2
• Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL SubjectsActive, not recruitingNCT02825836Phase 1/2
• A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer PatientsCompletedNCT02825563Phase 1
• Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLCStatus unknownNCT02824952Phase 2
• A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR MutationsStatus unknownNCT02824458Phase 3
• Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion"CompletedNCT02824133Phase 1/2
• Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN LossTerminatedNCT02822482Phase 1/2
• First-in-Human Safety, PK, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy VolunteersCompletedNCT02821624Phase 1
• Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and ChondrosarcomaCompletedNCT02821507Phase 2
• Omental Islet TransplantCompletedNCT02821026Phase 1/2
• The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR MutationStatus unknownNCT02820116Phase 2
• MEDI4736 Combinations in Metastatic Renal Cell CarcinomaCompletedNCT02819596Phase 2
• TD-1473 for Active Ulcerative Colitis (UC)CompletedNCT02818686Phase 1
• A Study of LY3023414 Formulations and the Effect of FoodCompletedNCT02818335Phase 1
• Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced MelanomaTerminatedNCT02818023Phase 1
• Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and PrednisoneWithdrawnNCT02815059Phase 1
• The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCCCompletedNCT02814461Phase 1
• Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCTCompletedNCT02812940Phase 2
• Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/AmplificationWithdrawnNCT02812693Phase 1/2
• Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated MalignanciesWithdrawnNCT02812056Phase 1
• Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNAStatus unknownNCT02811354Phase 2
• Bosutinib in Elderly Chronic Myeloid LeukemiaCompletedNCT02810990Phase 2
• A Study of Anlotinib in Patients With Hepatocellular CarcinomaStatus unknownNCT02809534Phase 2
• Ph II Nintedanib vs. Ifosfamide in Soft Tissue SarcomaTerminatedNCT02808247Phase 2
• Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy SubjectsCompletedNCT02807116Phase 1
• PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy SubjectsCompletedNCT02807077Phase 1
• To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy SubjectsCompletedNCT02807051Phase 1
• ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial MetabolismCompletedNCT02806817Early Phase 1
• A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)CompletedNCT02806648Phase 2
• PTCy and Ruxolitinib GVHD Prophylaxis in MyelofibrosisCompletedNCT02806375Phase 1/2
• Palbociclib and FES PETCompletedNCT02806050Phase 2
• PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker DiscoveryCompletedNCT02804776Phase 2
• Monotherapy With Rapamycin in Long-standing Type 1 DiabetesCompletedNCT02803892Phase 2
• Investigate Absorption, Metabolism, Excretion, and Mass Balance of PacritinibCompletedNCT02803762Phase 1
• Icotinib Hydrochloride Cream in Patients With Mild to Moderate PsoriasisCompletedNCT02801435Phase 1
• The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of RegorafenibCompletedNCT02800330Phase 4
• A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer SubjectsCompletedNCT02797977Phase 1/2
• Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins LymphomaTerminatedNCT02793583Phase 2/3
• A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid TumorsCompletedNCT02792465Phase 1
• Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT02791919Phase 1
• Clinical Trial to Investigate Pharmacokinetics, Metabolomics and Biomarker in Elderly After UDCA AdministrationStatus unknownNCT02789644Phase 1
• Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian CancerCompletedNCT02788708Phase 1
• Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid LeukemiaTerminatedNCT02782403Phase 1
• AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT02780830Phase 1
• Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung CancerStatus unknownNCT02780778Phase 2/3
• Testing Lenvatinib in Patients With Adenoid Cystic CarcinomaActive, not recruitingNCT02780310Phase 2
• Next Generation Personalized Neuroblastoma TherapyTerminatedNCT02780128Phase 1
• Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid MalignanciesWithdrawnNCT02780011Phase 1
• A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast CancerActive, not recruitingNCT02779751Phase 1
• A Study of Merestinib (LY2801653) in Healthy ParticipantsCompletedNCT02779738Phase 1
• A Study of AL2846 on Tolerance and PharmacokineticsStatus unknownNCT02779699Phase 1
• Conmana Combined With Thalidomide to Treat NSCLCStatus unknownNCT02778893Phase 4
• A Study of Prexasertib (LY2606368) in Participants With Advanced CancerCompletedNCT02778126Phase 1
• Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal CancersCompletedNCT02777710Phase 1
• Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy SubjectsCompletedNCT02777008Phase 1
• A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GISTStatus unknownNCT02776878Not applicable
• A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant ChemotherapyStatus unknownNCT02776527Phase 4
• A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and NeckStatus unknownNCT02775370Phase 2
• Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell CarcinomaTerminatedNCT02775006Phase 3
• Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon CancerWithdrawnNCT02774512Early Phase 1
• A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.Status unknownNCT02774200Phase 2
• A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal CancerStatus unknownNCT02773524Phase 3
• MEK162 in Combination With Capecitabine in Advanced Biliary Tract CancerCompletedNCT02773459Phase 1/2
• A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment FailureStatus unknownNCT02772029Phase 1/2
• Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLCStatus unknownNCT02771314Phase 2
• Ruboxistaurin in New York Heart Failure Classification III-IV PatientsWithdrawnNCT02769611Phase 1/2
• Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNACompletedNCT02769286Phase 2
• Intermittent Selumetinib for Uveal MelanomaCompletedNCT02768766Phase 1
• Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast CancerStatus unknownNCT02768415Phase 2
• A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced MelanomaCompletedNCT02768207Phase 2
• eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingNCT02767804Phase 3
• SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung CancerTerminatedNCT02766140Phase 3
• Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy SubjectsCompletedNCT02765724Phase 1
• Apatinib Dose Titration in Advanced or Metastatic Gastric CancerCompletedNCT02764268Not applicable
• A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and MetforminCompletedNCT02760342Phase 1
• Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by SurgeryCompletedNCT02760030Phase 2
• A Phase I Trial of HS-10241 in Solid TumorsCompletedNCT02759640Phase 1
• Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLLCompletedNCT02758665Phase 2
• Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)Status unknownNCT02758587Phase 1/2
• Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCLWithdrawnNCT02757248Phase 1
• Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic LeukemiaActive, not recruitingNCT02756897Phase 2
• A Clinical Trial of Buparlisib and Ibrutinib in LymphomaCompletedNCT02756247Phase 1
• A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder CancerCompletedNCT02753309Early Phase 1
• Study of Galunisertib in Healthy ParticipantsCompletedNCT02752919Phase 1
• A Phase I Additional Study of Anlotinib on Tolerance and PharmacokineticsStatus unknownNCT02752516Phase 1
• Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized StudyStatus unknownNCT02748707Phase 2
• Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular CarcinomaTerminatedNCT02748304Not applicable

← Protein Kinase Inhibitors overview